FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.

Also called NCT03490201

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 592 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03490201
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Czechia, France, Germany, Italy, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03490201. Randomized; single masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2024-04-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study
Acronym
LESS-VT
Condition
Ventricular Tachycardia
Intervention (Device)
Market Approved RF Ablation System
Intervention (Device)
FlexAbility SE Ablation Catheter
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03490201
Content hash
a360bd3a55b5b42de584a3aea3f3c8eb09c725b9c323effdb72c150f1aceb94a